Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Mayne Pharma sells Adelaide plant to focus on US
Mayne Pharma has agreed to sell its Adelaide manufacturing plant as part of a $55 million deal to offload its international segment to Genesis Capital following pressure from shareholders to break up the company after a $672 million takeover bid…
Atyr Pharma: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $18.3 million in its third quarter. The San Diego-based company said it had a loss of $7.43 per share. Atyr Pharma shares have declined 81% since…
Eton Pharma (ETON) Q3 2026 Earnings Call Transcript
Chief Business Officer - David Krempa Chief Executive Officer - Sean Brynjelsen Chief Commercial Officer - Ipek Trinkaus Chief Financial Officer - Judith Matthews Net Revenue -- $57.9 million, representing 158% year-over-year growth driven by the…
ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
President and Chief Executive Officer - Nikhil Lalwani Senior Vice President and Chief Financial Officer - Stephen Carey Senior Vice President and Head of ANI's Rare Disease Business - Christopher K. Mutz Chief Medical Officer - Gary Powell…
Acadia Pharma (ACAD) Q3 2026 Earnings Call Transcript
Senior Vice President, Investor Relations and Corporate Communications - Al Kildani Chief Executive Officer - Catherine Owen Adams Chief Commercial Officer - Tom Garner Senior Vice President and Head of Clinical Development - Sanjeev Pathak Chief…
Ginkgo reaffirms 2026 cash burn guidance of $125M-$150M while outlining first pharma autonomous lab sale to Novo Nordisk (NYSE:DNA)
Earnings Call Insights: Ginkgo Bioworks (DNA) Q3 2026 “Over the last few years, we've been going through a transformation with this focus on autonomous labs, and that was really our goal in 2026. I would say I think that succeeded very…
Royalty Pharma (NASDAQ:RPRX) Given New $78.00 Price Target at Citigroup
Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price lifted by Citigroup from $70.00 to $78.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a 'buy' rating on the biopharmaceutical…
Urogen Pharma (NASDAQ:URGN) Stock Rated 'Moderate Buy' by Wall Street Analysts
Urogen Pharma (NASDAQ:URGN - Get Free Report) has earned a consensus recommendation of 'Moderate Buy' from the ten ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell…
Guggenheim Has Lowered Expectations for Urogen Pharma (NASDAQ:URGN) Stock Price
Urogen Pharma (NASDAQ:URGN - Get Free Report) had its price objective lowered by analysts at Guggenheim from $58.00 to $56.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a 'buy' rating on the stock.
NewAmsterdam Pharma (NASDAQ:NAMS) Given New $46.00 Price Target at Needham & Company LLC
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) had its price target lowered by stock analysts at Needham & Company LLC from $48.00 to $46.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a 'buy' rating on the…
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income (NYSE:NVO)
Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers, supporting a value-driven investment thesis.
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It (RVMD)
Revolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper further upside until sustained…
Moderna to report Q3 amid valuation debate, cancer vaccine results: What to expect (MRNA:NASDAQ)
Moderna (MRNA) will report its third-quarter earnings on November 5, after the closing bell, amid heated discussions around the firm's valuation and the release of the much-discussed cancer vaccine results. Wall Street expects the pharma giant to…
Doximity (DOCS) Q2 2027 Earnings Call Transcript
Investor Relations - Perry Scott Gold Cofounder and Chief Executive Officer - Jeffrey A. Tangney Chief Financial Officer - Matthew Sonefeldt Revenue -- $174.5 million, representing 4% year-over-year growth and exceeding the high end of quarterly…
Emerson Electric: LNG And Reshoring Tailwinds Justify Buying Despite A Rich Multiple (EMR)
Emerson Electric is positioned for durable, margin-accretive growth driven by industrial reshoring and global energy expansion. EMR's improving margin profile, strong cash generation, and shareholder returns through buybacks and dividends enhance…
Receive a Daily briefing on Pharma Industry News
Get Started